Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Early Relapse Following ASCT for Patients with MM: Identification of Predictor Factors in the Era of Novel Agents

Victor Jimenez-Zepeda, MD, Peter Duggan, MD, Paola Neri, MD PhD, Ahsan Chaudhry, MD, Jason Tay, MD FRCPC MSc, Joanne Luider, Fariborz Rashid-Kolvear, PhD, Nizar J. Bahlis, MD

Blood (2016) 128 (22): 5818.

https://doi.org/10.1182/blood.V128.22.5818.5818

Published: 2016

Journal Articles

Immunoglobulin Recovery after ASCT for Patients with Multiple Myeloma: Impact on Overall Survival and Progression-Free Survival

Victor Jimenez-Zepeda, MD, Peter Duggan, MD, Paola Neri, MD PhD, Ahsan Chaudhry, MD, Jason Tay, MDFRCPC MSc, Nizar J. Bahlis, MD

Blood (2016) 128 (22): 2263.

https://doi.org/10.1182/blood.V128.22.2263.2263

Published: 2016

Journal Articles

Bortezomib-High Dose Melphalan Conditioning for the Treatment of MM Patients Undergoing ASCT

Victor Jimenez-Zepeda, MD, Peter Duggan, MD, Paola Neri, MD PhD, Ahsan Chaudhry, MD, Jason Tay, MDFRCPC MSc, Joanne Luider, Nizar J. Bahlis, MD

Blood (2016) 128 (22): 2273.

https://doi.org/10.1182/blood.V128.22.2273.2273

Published: 2016

Journal Articles

Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Followed By ASCT with HDM or Bor-HDM Conditioning Regimens: A Single Center Experience

Victor H Jimenez-Zepeda, MD, Peter Duggan, MD, Paola Neri, MD PhD, Ahsan Chaudhry, MD, Joanne Luider, Nizar J Bahlis, MD

Blood (2015) 126 (23): 5492.

https://doi.org/10.1182/blood.V126.23.5492.5492

Published: 2015

Journal Articles

Bortezomib and High Dose Melphalan (Bor-HDM) Compared to HDM Conditioning for the Treatment of Transplant Eligible Multiple Myeloma: Report from a Single Center

Victor H Jimenez-Zepeda, MD, Peter Duggan, MD, Paola Neri, MD PhD, Ahsan Chaudhry, MD, Marcia Culham, RN, BSN, NP, Joanne Luider, Fariborz Rashid-Kolvear, PhD, Nizar J Bahlis, MD

Blood (2015) 126 (23): 3189.

https://doi.org/10.1182/blood.V126.23.3189.3189

Published: 2015

Journal Articles

FluBup-ATG-TBI for High-Risk or Advanced Adult ALL in Remission: A Retrospective Review of a Mature Cohort.

Andrew Daly, MD, FRCPC, Douglas A. Stewart, MD, FRCPC, Ahsan Chaudhry, MD, Nizar J Bahlis, MD, FRCPC, Christopher Brown, MD, FRCPC, Peter Duggan, MD, FRCPC, Michelle Geddes, MD, FRCPC, Mary Lynn Savoie, MD, FRCPC, Jan Storek, MD, PhD, Maggie Yang, James A. Russell, MD, FRCPC

Blood (2009) 114 (22): 3384.

https://doi.org/10.1182/blood.V114.22.3384.3384

Published: 2009

Journal Articles

Effect of Donor on Outcomes after Myeloablative Conditioning with Daily IV Busulfan and Fludarabine (FLUBUP) +/− TBI with Thymoglobulin: Transplants from Mismatched Unrelated Donors (MMUD) Have Worse Survival Due to Higher Transplant-Related Mortality (TRM).

James A. Russell, FRCP, Leanne Kmet, MSc, Mary Lynn Savoie, MD, Nizar J. Bahlis, MD, M. Ahsan Chaudhry, MD, Diana M. Quinlan, BN, Michelle Geddes, MD, A. Robert Turner, MD, Loree M. Larratt, MD, Christopher Brown, MD, Jan Storek, MD, Douglas A. Stewart, MD

Blood (2006) 108 (11): 5398.

https://doi.org/10.1182/blood.V108.11.5398.5398

Published: 2006

Journal Articles

Hematopoietic Stem Cell Transplantation (SCT) for Hematologic Malignancy from Matched Related Donors (MRD) with a Myeloablative Once Daily IV Busulfan (Bu)/Fludarabine (Flu) Based Regimen (FLUBUP) with Thymoglobulin: Outcomes in 200 Patients with over One Year Follow-Up.

James A. Russell, FRCP, Nizar J. Bahlis, MD, Mary Lynn Savoie, MD, M. Ahsan Chaudhry, MD, A. Robert Turner, MD, Loree M. Larratt, MD, Diana M. Quinlan, BN, Christopher Brown, MD, Alexander Balogh, MD, Jan Storek, MD, Michelle Geddes, MD, Douglas A. Stewart, MD

Blood (2006) 108 (11): 3009.

https://doi.org/10.1182/blood.V108.11.3009.3009

Published: 2006

Journal Articles

Total Body Irradiation (TBI) Added to Fludarabine/Busulfan/Antithymocyte Gobulin (FLUBUP/ATG) Conditioning Increases Overall Survival and Relapse-Free Survival in Patients with Acute Myeloid Leukemia (AML) Receiving Allogeneic Stem Cell Transplants.

Mary Lynn Savoie, MD, Alexander Balogh, MD, Ahsan Chaudhry, MD, Douglas A. Stewart, MD, Nizar J. Bahlis, MD, Jan Storek, MD,PhD, Christopher Brown, MD,PhD, Diana Quinlan, RN, Leanne Kmet, PhD, Loree M. Larratt, MD, A. Robert Turner, MD, James A. Russell, FRCPE

Blood (2006) 108 (11): 3010.

https://doi.org/10.1182/blood.V108.11.3010.3010

Published: 2006

Journal Articles

Transplant-Related Mortality in Patients ≥50 Years of Age Is No Lower after Transplantation from Young Fully Matched Unrelated Donors (MUD) Than from Matched Siblings When All Patients Are Given the FLUBUP Regimen with Thymoglobulin.

James A. Russell, FRCP, M. Ahsan Chaudhry, MD, Diana M. Quinlan, BN, A. Robert Turner, MD, Loree M. Larratt, MD, Michelle Geddes, MD, Jan Storek, MD, Mary Lynn Savoie, MD, Christopher Brown, MD, Nizar J. Bahlis, MD, Douglas A. Stewart, MD

Blood (2006) 108 (11): 3159.

https://doi.org/10.1182/blood.V108.11.3159.3159

Published: 2006

Journal Articles

High Busulfan Exposure Is Associated with Worse Outcome in a Daily IV Busulfan and Fludarabine Transplant Regimen.

Michelle Geddes, MD, Shahbal B. Kangarloo, PhD, Farrukh Naveed, BSc, Quinlan M. Diana, RN, Ahsan Chaudhry, MD, Mary Lynn Savoie, MD, Nizar J. Bahlis, MD, Douglas A. Stewart, MD, Christopher Brown, MD, PhD, Jan Storek, MD, PhD, Borje Andersson, MD, PhD, James A. Russell, MA, MB, B. Chir

Blood (2006) 108 (11): 313.

https://doi.org/10.1182/blood.V108.11.313.313

Published: 2006

Journal Articles

Hematopoietic Stem Cell Transplantation (SCT) for Hematologic Malignancy from 10/10 Matched Unrelated Donors (MUD) with a Myeloablative Once Daily IV Fludarabine (Flu)/Busulfan Based Regimen (FLUBUP) with Thymoglobulin: Outcomes According to Stem Cell Source.

James A. Russell, FRCP, M. Ahsan Chaudhry, MD, Michelle Geddes, MD, Nizar J. Bahlis, MD, Mary Lynn Savoie, MD, Loree M. Larratt, MD, Diana M. Quinlan, BN, A. Robert Turner, MD, Alexander Balogh, MD, Jan Storek, MD, Christopher Brown, MD, Douglas A. Stewart, MD

Blood (2006) 108 (11): 3140.

https://doi.org/10.1182/blood.V108.11.3140.3140

Published: 2006

Journal Articles

Adult Recipients of Matched Related Donor Blood Cell Transplants Given Pretransplant Antithymocyte Globulin Have Less Graft-Versus-Host Disease and Transplant-Related Mortality: Follow-Up of a Matched Pair Analysis.

James A. Russell, FRCP, Loree M. Larratt, MD, A. Robert Turner, MD, M. Ahsan Chaudhry, MD, Oluyeme Jeje, MD, Donald Morris, MD, Christopher Brown, MD, Diana M. Quinlan, BN, Douglas A. Stewart, MD

Blood (2006) 108 (11): 2865.

https://doi.org/10.1182/blood.V108.11.2865.2865

Published: 2006

Journal Articles

Fludarabine-Busulfan Conditioning and In Vivo T-Cell Depletion with Reduced Dose of ATG Followed by Allografting Induces Durable Responses in Patients with Advanced Multiple Myeloma with No Grade III-IV aGvHD.

Nizar J. Bahlis, MD, Douglas A. Stewart, MD, Mary Lynn Savoie, MD, Christopher Brown, MD, Andrew Daly, MD, Ahsan Chaudhry, MD, Jan Storek, MD, PhD, James A. Russell, MBBChir, FRCPE

Blood (2006) 108 (11): 3029.

https://doi.org/10.1182/blood.V108.11.3029.3029

Published: 2006

Journal Articles

Dose Intensive Induction Chemotherapy Does Not Decrease Tumor Contamination of Autograft or Improve Survival for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant.

Farzana A. Sayani, MD, Nizar J. Bahlis, MD, Peter Faris, PhD, Mary Lynn Savoie, MD, Ahsan Chaudhry, MD, Oluyemi Jeje, MD, Christopher B. Brown, MD, James A. Russell, MBBChir, FRCPE, Douglas A. Stewart, MD

Blood (2005) 106 (11): 2932.

https://doi.org/10.1182/blood.V106.11.2932.2932

Published: 2005

Journal Articles

The Influence of Adding Low-Dose (400cGy) Total Body Irradiation (TBI) on Outcomes of Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukaemia (AML) with Myeloablative Conditioning Incorporating Daily Intravenous Busulfan, Fludarabine and Low-Dose Antithymocyte Globulin.

Mary Lynn Savoie, MD, Alexander Balogh, MD, M. Ahsan Chaudhry, MD, Oluyemi Jeje, MD, Douglas A. Stewart, MD, Nizar J. Bahlis, MD, Jan Storek, MD, PhD, Christopher B. Brown, MD, PhD, Diana M. Quinlan, A. Robert Turner, MD, Loree M. Larratt, MD, James A. Russell, MBBChir, FRCPE

Blood (2005) 106 (11): 2733.

https://doi.org/10.1182/blood.V106.11.2733.2733

Published: 2005

Journal Articles

Salvage Thalidomide Improves Survival of Relapsed Multiple Myeloma Patients When Compared to Other Salvage Chemotherapies: A Retrospective Analysis.

Nizar J. Bahlis, MD, Lynn Savoie, MD, Ahsan Chaudhry, MD, Karen Valentine, MD, Deidre Jenkins, MD, Christopher Brown, MD, Jim Russell, MD, Douglas Stewart, MD

Blood (2005) 106 (11): 5144.

https://doi.org/10.1182/blood.V106.11.5144.5144

Published: 2005

Journal Articles

High Dose Thiotepa, Busulfan, Cyclophosphamide (TBC) and Autologous Hematopoietic Stem Cell Transplantation (ASCT) without Whole Brain Radiotherapy (WBRT) for Primary Central Nervous System Lymphoma (PCNSL).

Douglas A. Stewart, MD, FRCPC, Peter Forsyth, MD, Ahsan Chaudhry, MD, Oluyemi Jeje, MD, Donald Morris, MD, FRCPC, Lynn Savoie, MD, FRCPC, Chris Brown, MD, FRCPC, James R. Russell, MB, FRCPC

Blood (2004) 104 (11): 911.

https://doi.org/10.1182/blood.V104.11.911.911

Published: 2004

Journal Articles

A Prospective Phase II Comparison of Stem Cell Source Using Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) RE—Induction, Then High Dose Fludarabine, Busulfan (FLUBU) and Autologous (ASCT) or Allogeneic (AlloSCT) Hematopoietic Blood Stem Cell Transplantation for Mantle Cell (MCL) and Relapsed Low-Grade B-Cell Non-Hodgkin’s Lymphoma (NHL).

Douglas A. Stewart, MD, FRCPC, Michael Voralia, MD, FRCPC, Ahsan Chaudhry, MD, Oluyemi Jeje, MD, Donald Morris, MD, FRCPC, Lynn Savoie, MD, FRCPC, Chris Brown, MD, FRCPC, Wanda Hasagawa, MD, FRCPC, Nizar Bahlis, MD, James R. Russell, MB, BChir, FRCPC

Blood (2004) 104 (11): 915.

https://doi.org/10.1182/blood.V104.11.915.915

Published: 2004

NARROW

Early Relapse Following ASCT for Patients with MM: Identification of Predictor Factors in the Era of Novel Agents

Immunoglobulin Recovery after ASCT for Patients with Multiple Myeloma: Impact on Overall Survival and Progression-Free Survival

Bortezomib-High Dose Melphalan Conditioning for the Treatment of MM Patients Undergoing ASCT

Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Followed By ASCT with HDM or Bor-HDM Conditioning Regimens: A Single Center Experience

Bortezomib and High Dose Melphalan (Bor-HDM) Compared to HDM Conditioning for the Treatment of Transplant Eligible Multiple Myeloma: Report from a Single Center

FluBup-ATG-TBI for High-Risk or Advanced Adult ALL in Remission: A Retrospective Review of a Mature Cohort.

Effect of Donor on Outcomes after Myeloablative Conditioning with Daily IV Busulfan and Fludarabine (FLUBUP) +/− TBI with Thymoglobulin: Transplants from Mismatched Unrelated Donors (MMUD) Have Worse Survival Due to Higher Transplant-Related Mortality (TRM).

Hematopoietic Stem Cell Transplantation (SCT) for Hematologic Malignancy from Matched Related Donors (MRD) with a Myeloablative Once Daily IV Busulfan (Bu)/Fludarabine (Flu) Based Regimen (FLUBUP) with Thymoglobulin: Outcomes in 200 Patients with over One Year Follow-Up.

Total Body Irradiation (TBI) Added to Fludarabine/Busulfan/Antithymocyte Gobulin (FLUBUP/ATG) Conditioning Increases Overall Survival and Relapse-Free Survival in Patients with Acute Myeloid Leukemia (AML) Receiving Allogeneic Stem Cell Transplants.

Transplant-Related Mortality in Patients ≥50 Years of Age Is No Lower after Transplantation from Young Fully Matched Unrelated Donors (MUD) Than from Matched Siblings When All Patients Are Given the FLUBUP Regimen with Thymoglobulin.

High Busulfan Exposure Is Associated with Worse Outcome in a Daily IV Busulfan and Fludarabine Transplant Regimen.

Hematopoietic Stem Cell Transplantation (SCT) for Hematologic Malignancy from 10/10 Matched Unrelated Donors (MUD) with a Myeloablative Once Daily IV Fludarabine (Flu)/Busulfan Based Regimen (FLUBUP) with Thymoglobulin: Outcomes According to Stem Cell Source.

Adult Recipients of Matched Related Donor Blood Cell Transplants Given Pretransplant Antithymocyte Globulin Have Less Graft-Versus-Host Disease and Transplant-Related Mortality: Follow-Up of a Matched Pair Analysis.

Fludarabine-Busulfan Conditioning and In Vivo T-Cell Depletion with Reduced Dose of ATG Followed by Allografting Induces Durable Responses in Patients with Advanced Multiple Myeloma with No Grade III-IV aGvHD.

Dose Intensive Induction Chemotherapy Does Not Decrease Tumor Contamination of Autograft or Improve Survival for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant.

The Influence of Adding Low-Dose (400cGy) Total Body Irradiation (TBI) on Outcomes of Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukaemia (AML) with Myeloablative Conditioning Incorporating Daily Intravenous Busulfan, Fludarabine and Low-Dose Antithymocyte Globulin.

Salvage Thalidomide Improves Survival of Relapsed Multiple Myeloma Patients When Compared to Other Salvage Chemotherapies: A Retrospective Analysis.

High Dose Thiotepa, Busulfan, Cyclophosphamide (TBC) and Autologous Hematopoietic Stem Cell Transplantation (ASCT) without Whole Brain Radiotherapy (WBRT) for Primary Central Nervous System Lymphoma (PCNSL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only